A range of particulate delivery systems have been considered as vaccine adjuvants. Of these systems, liposomes offer a range of advantages including versatility and flexibility in design format and their ability to incorporate a range of immunomodulators and antigens. Here we briefly outline research, from within our laboratories, which focused on the systematic evaluation of cationic liposomes as vaccines adjuvants. Our aim was to identify physicochemical characteristics that correlate with vaccine efficacy, with particular consideration of the interlink between depot-forming action and immune responses. A variety of parameters were investigated and over a range of studies we have confirmed that cationic liposomes, based on dimethyldioctadecylammonium bromide and trehalose 6,6'-dibehenate formed a depot at the injection site, which stimulates recruitment of antigen presenting cells to the injection site and promotes strong humoral and cell-mediated immune responses. Physicochemical factors which promote a strong vaccine depot include the combination of a high cationic charge and electrostatic binding of the antigen to the liposome system and the use of 2 lipids with high transition temperatures, which form rigid bilayer vesicles. Reduction in vesicle size of cationic vesicles did not promote enhanced drainage from the injection site.
Liposomes as vaccine adjuvants
Of the range of delivery systems available, liposomes were the first delivery system to be described as being able to act as immunological adjuvants. 1 Liposomes are composed of lipid molecules which, when dispersed into an aqueous phase, form bilayered vesicles ( Figure 1 ).
These lipid building-blocks are composed of three sections (tail, linker and head) and due to the hydrophobic and hydrophilic natures of the tail and head respectively, the water-loving head group is directed outwards, thus forming liposomes. Liposomes can be manufactured in a wide range of morphologies from single to multi-lamellar in structure and ranging in size from ~50 nm up to several microns in size ( Figure 1 ).
Figure 1:
Schematic outline of the formation of liposomes. Lipid molecules, when dispersed in an aqueous phase form bilayers vesicles that can be prepared in a range of sizes from larger multilamellar vesicles, through to small unilamellar vesicles.
Liposomes are an ideal vaccine delivery system due to their particulate nature, flexibility in formulation, ability to incorporate a range of moieties including immunogenic molecules and
The geometry of liposomes is principally determined by their method of manufacturing and their lipid composition. For example, size reduction of vesicles can include sonication, highshear homogenization or high pressures whereby disruptive energy causes large vesicles to rearrange into smaller ones. An overview of a range of liposome production methods are shown in Figure 2 . However, these traditional methods of liposome synthesis raise several difficulties e.g. mechanical stresses, difficultly in up-scaling and methods that rarely lead to size-uniform liposomes. 3 To address these issues, the area of microfluidics, and its associated development of novel lab-on-a-chip based devices, has gainedincreasing attention over recent decades. Besides saving time and money, the use of microfluidics methods reduces space and sample volume ( Figure 3 ). In terms of developing liposomal adjuvants, a key consideration is their ability to carry and delivery their antigen payload to the appropriate target site. Again, a range of methods have been investigated to promote or improve antigen and liposome association e.g. the dehydration-rehydration. 4 A relatively simple and flexible option is to adopt electrostatic interactions to support antigen loading, where the liposomes are designed with the appropriate surface charge to electrostatically adsorb antigen. 5 To exploit this method, the overall charge of a peptide or protein must be known; this will be dependent on its amino acids and will change according to the pH of the solution it is suspended in. However, most protein adjuvants have an overall negative charge making cationic liposomes an appropriate design choice.
associated with a functional enhancement of the APCs. This was shown by measuring the increase in gamma interferon (IFNγ) production and cellular proliferation of purified autologous DO11.10 T-cells transgenic for a T-cell receptor recognizing a major histocompatibility complex (MHC) class II-restricted OVA-epitope (OVA323-339). Both proliferation and IFNγ production was increased upon interaction with either murine BMDCs or purified B-cells, stimulated with OVA adsorbed to DDA. 17, 18 To further enhance the potency of DDA liposomes, a second component, D-(+)-trehalose 6,6'-dibehenate (TDB) can be added. 13 TDB is a synthetic analog of trehalose-6,6-dimycolate, a immunostimulatory component of Mycobacterium tuberculosis. TDB has two saturated fatty-acid chains of 22 carbons (behenyl), each replacing the branched mycobacterial mycolic acids of >70 carbons ( Figure 4 ). These two behenyl chains are linked by ester bonds to carbon number 6 of each of the two glucopyranose rings making up the trehalose head group (Figure 4) . TDB has been shown to retain much of the bioactivity of the native form, whilst showing less toxicity as a result of the shorter fatty acid chains. 19, 20 Combination with DDA it is an efficient adjuvant for TB subunit vaccines, 13 inducing a strong IFNγ response, considered to be the key cytokine for induction of a Th 1 immune response and essential for effective anti-mycobacterial immunity. 21, 22 Interestingly TDB does not only enhance the immunogenicity of the DDA liposomal systems. 7 Having shown that DDA:TDB could be effectively prepared in a sterile and stabile format via lyophilization and gamma-sterilization, 23, 24 the contributing role of TDB to the DDA membranes both in an aqueous 25 and freeze-dried format 26 was shown to result from the higher attractive forces between the trehalose head group of TDB and water compared to the quaternary ammonium head group of DDA and water. 
Systematically investigating the formulation parameters controlling the efficacy of DDA:TDB as a liposomal adjuvant
Building on the demonstrated potential of the DDA/TDB system developed by the Staten Serum Institut (e.g. reference 13), a series of collaborative studies were undertaken to investigate the principles behind the efficacy of this formulation, with one focus being consideration of physico-chemical attributes. Our aim was to identify formulation attributes that could be considered to act as correlates for efficacy. These investigations were based on early studies 7 IFNγ responses from blood lymphocytes isolated from immunized mice were significantly higher for DDA:TDB (11%), whilst IL-5 levels were significantly lower. In addition to potentiating the immune response of DDA liposomes, incorporation of TDB within the formulation was shown to effectively stabilize the DDA liposomes. 7 Given that this DDA:TDB combination was shown to be highly effective, this combination was also incorporated into a range of other particulate based systems including niosomes 33 and microspheres. 34, 35 Incorporation of DDA and TDB within either of these systems did not produce particulates with enhanced adjuvant properties compared to the liposomal DDA:TDB liposome formulation. Therefore, the next stage was to focus on the DDA:TDB liposome formulation and consider the role of its physico-chemical characteristics in it performance as an adjuvant, with particular reference to it biodistribution.
The impact of lipid choice -the controlling role of charge
The highly cationic nature of the DDA:TDB liposome formulation offers the advantage of these systems being able to electrostatically bind a range of antigens; however, we also proposed the hypothesis that this cationic charge would influence the biodistribution of the vesicles and their adsorbed antigen. Therefore, we undertook a range of studies applying a relatively simple, effective and reproducible method to follow the biodistribution of the liposomes and their associated antigen using a dual-radiolabeling method developed within our laboratories, where the liposomes are labeled with 3 H and the antigen with 125 I. 36 Using this method we were able to demonstrate that whilst antigen delivered without liposomes were removed quickly from the body, liposomes based on DDA promoted a depot at the injection site (both after sub-cutaneous or intramuscular injection) and that TDB did not significantly influence this deport effect. 37 However, the presence of TDB in the DDA liposomes increased the influx of monocytes to the site of injection, and the subsequent draining of the liposomal adjuvant to the popliteal lymph nodes, in addition to inducing a powerful Th1 response. 37 The impact on vesicle charge on the deposition of antigen at the injection site was further considered by comparing cationic DDA:TDB liposomes with a comparable near-neutral liposome formulation composed of Distearoylphosphatidylcholine (DSPC) and TDB (11 mol%). 38 This study demonstrates that the cationic nature of the vesicles promotes the retention of the liposomal components at the site of injection, with the DSPC:TDB formulation being more rapidly cleared. Furthermore, the electrostatic adsorption of antigen to the vesicles was demonstrated to be a key requirement for antigen retention. Not only did the neutral liposomes give poor antigen absorption and retention at the injection site, cationic liposomes which were unable to absorb a cationic model antigen (as would be expected) also failed to promote an antigen depot, despite the liposomes being retained at the injection site. 38 However, distearoylphosphatidylcholine-based liposomes entrapping antigen within the vesicles were shown to offer a potential alternative to cationic-based systems, especially for the delivery of zwitterionic or cationic molecules. 39 
Choosing the cationic lipid component
Given that we had demonstrated the controlling role of the cationic lipid in the promotion of a depot at the site of injection, the next consideration addressed whether this was applicable to a range of cationic formulations. Therefore the ability of 3β-[N-(N′,N′-
propane (DOTAP), or DDA liposomes incorporating immunomodulating trehalose dibehenate (TDB) to form an antigen depot at the site of injection (SOI) and to induce immunological recall responses against co-administered tuberculosis vaccine antigen was investigated. 40 Despite all three formulations being cationic in nature, differences in the biodistribution of these vesicles were noted, with the DOTAP formulation draining more rapidly from the injection site compared to the DDA or DC-Chol formulations. This was reflected in a slower drainage to the local lymphoid tissue. This was attributed to the DOTAP liposomes having a lower transition temperature and therefore more fluid in nature, thus promoting easier drainage from the injection site. This was confirmed by comparing liposomes prepared using DDA with liposomes prepared with its unsaturated analog dimethyldioleoylammonium bromide (DODA), which contained one unsaturated C=C bound in each of the lipophilic acyl chains. By comparing the delivery properties of liposomes prepared using these two lipids, liposomes which were rigid (DDA:TDB liposomes) or fluid (DODA:TDB liposomes) in nature at physiological temperatures could be considered. 41 Through a series of studies it was shown that these two different formulations showed major differences in their ability to drive a Th1 immune response. The rigid DDA-based liposomes retained higher levels of antigen at the injection site, resulting in a continuous attraction of antigen-presenting cells that expressed elevated levels of the co-stimulatory molecules CD40
and CD86. 41 Overall the rigid, DDA-liposomes induced 100-fold higher Th1 responses than the fluid DODA liposome counterparts, confirming that a range of physico-chemical
properties have a major influence on the efficacy of liposomal adjuvants.
3.3.Enhancing delivery of DDA:TDB to the target site
While all the studies undertaken with the DDA:TDB had proved it gave strong Th1 responses and formed a strong depot at the site of injection, this did not necessarily demonstrate a direct correlation between the these two attributes, and enhancing the delivery of DDA:TDB + antigen to APC should further boost its potency. This was nicely demonstrated by a study led by Johansen's group 42 , where the immune responses achieved by DDA:TDB when administered via the sub-cutaneous, intradermal, intramuscular or intra-lymphatic routes.
This study showed that the route of administration promoted no notable differences in IgG1.
However, the administration route had a major influence on Th 1 responses; intra-lymphatic injection gave strong early IgG2a responses and significantly higher IFNγ secretion from splenocytes collected from immunized mice via this route compared to the other routes. 42 This suggested that while the highly effective DDA:TDB liposome formulation formed a strong depot effect at the injection site, trafficking of this formulation to the draining lymphatics would enhance vaccine efficacy.
The role of particulate size in the biodistribution of DDA:TDB liposomal adjuvants
When considering the biodistribution of liposomes, size is often shown to have a significant impact. Hence, liposome size was also an important attribute to consider. In the above studies the DDA:TDB liposomes studied were around 500 -600 nm in size, therefore consideration of the impact of the size of the DDA:TDB vesicles on their role as adjuvants was also investigated. 43 DDA:TDB liposomes were prepared in the following size ranges: small (<200 nm), medium (500-600 nm), and large (~1500 nm). No significant difference in the drainage of the liposomes or their adsorbed antigen from the site of injection was seen between the different sized liposomes. However, significantly higher levels (but still relatively low amounts of the total dose) of the smaller liposomes were noted at the popliteal lymph node, 6
hours after injection. 43 This was shown to be independent to cellular phagocytosis, as macrophage uptake of these various liposomes was not shown to be size-dependent. 43 This would suggest that due to their cationic nature, and independent of their size, the vesicles aggregate after administration, due to interaction with interstitial proteins which are generally anionic in nature, thus prohibiting their clearance from the site of injection.
Retaining the DDA component but masking its cationic nature -pegylated

DDA:TDB
Given that the depot effect had been shown to be primarily due to the cationic nature of the vesicles, which results in electrostatic adsorption of the antigen and aggregation of the vesicles at the site of injection, a second method to promote drainage (yet retain the DDA content of the DDA:TDB:antigen formulation) to the lymphatics was considered. A series of studies were undertaken where the cationic DDA component of the liposomes was retained, yet the cationic nature masked with polyethylene glycol. Polyethylene glycol (PEG) is the most widely used hydrophilic polymer for the steric stabilization of liposome drug delivery systems. It is a linear polyether diol with many useful properties, including the ability to be conjugated to a liposomal surface to create a steric, hydrophilic barrier which can enhance increasing half-life of the liposomes, through steric stabilization. 44 Coating of liposomes with PEG (often referred to as PEGylation), is exploited in therapeutic products such as Caelyx, which is a PEGylated liposomal delivery system for doxorubicin. PEG can be incorporated onto the surface of liposomes in different ways, but the most widely used method at present is to anchor the polymer in the liposomal membrane via a cross-linked lipid (i.e. PEG-
DDA:TDB liposomes were prepared with increasing PEG concentrations (0 to 25 mol%).
This resulted in the cationic zeta potential of the vesicles dropping from ~55 mV for DDA:TDB down to 39 mV with the addition of 10% PEG, and to 3 mV when 25% PEG was added. 45 This drop in zeta potential results in a reduction in both the liposome and antigen depot at the injection site, and reduced monocyte influx to the injection site. However, whilst
PEGylation of DDA:TDB tended to promote an increased drainage of liposomes to the local lymph node, this did not translate to an increased antigen delivery to the draining lymph nodes. 45 In terms of immune responses, whilst increasing PEG concentrations in the DDA:TDB liposomal adjuvant made no significant difference in IgG1 responses, both IgG2b
and IFNγ responses reduced with increasing PEG concentrations. 45 This suggested that PEGylation was able to block the formation at the site of injection, yet the PEGylated liposomes were less able to carry the antigen with them to the draining lymph nodes.
In an attempt to address this and improve co-delivery of the liposomes and antigen to the draining lymph nodes, a second series of PEGylated liposomes were prepared where the antigen was incorporated within the liposomes rather than surface adsorbed. 45 However, this did not significantly enhance antigen delivery to the PLN, nor change the immune-responses compared to the DDA:TDB formulations with the surface-adsorbed antigen. 45 To consider if a combination of size reduction and PEGylation of the vesicles could further modify the clearance kinetics of these liposomal adjuvants, DDA:TDB liposomes with and without PEGylation were also prepared as small unilamellar vesicles (SUV). 46 By using DDA:TDB:10% PEG vesicles which were ~150 nm in size, both liposome and antigen dose at the popliteal lymph node 4 days after injection was increased and earlier antibody responses noted. 46 The ability of PEGylation of small cationic liposomes to enhance drainage was also demonstrated with DNA vaccine carriers. Liposomes composed of phosphtidylcholine, dioleoylphosphatidylethanolamine and the cationic lipid DOTAP were prepared with entrapped OVA-encoding plasmid DNA; the introduction of PEG onto the surface of these small cationic vesicles resulted in enhanced lymphatic drainage after sub-cutaneous injection, but the immune responses measured were not improved when compared to non-PEGylated liposomes. 47 
The controlling role of the adjuvant depot on Th1 but not Th2 responses
A particular reference point in the above outlined studies was the ability of the liposomal formulation to form a depot at the site of injection and the overall design factors identified to control the formation of a depot at the site of injection for liposomal adjuvants are summarised in Figure 5 Until recently, it had been widely accepted that the activity of alumbased adjuvants was attributed to its ability to retain the antigen at the site of injection. 48 This theory was recently put into question through various studies which demonstrated that alum with non-adsorbed or adsorbed antigen gave rise to similar antibody responses 49, 50 and indeed removal of the alum injection site did not influence the subsequent immune response. 51 Through the above series of studies, we have systematically considered the correlation between the induction of immune responses and the ability of the liposomal formulation to promote depot formation. These studies demonstrate that 1) liposomes that promote a strong depot effect also potentiate a strong Th 1 response, and 2) Th2 responses generated by these liposomal adjuvants were not influenced by/reliant upon the depot formation. These findings are in line with the more recent understanding of Alum's adjuvant action, which predominately drives a Th2 response and appears to act independent of a depot. 
